Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Matinas Biopharma Hl (MTNB)

Matinas Biopharma Hl (MTNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,475
  • Shares Outstanding, K 217,483
  • Annual Sales, $ 1,100 K
  • Annual Income, $ -22,940 K
  • 60-Month Beta 1.52
  • Price/Sales 40.18
  • Price/Cash Flow N/A
  • Price/Book 2.29
Trade MTNB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.12
  • Most Recent Earnings $-0.03 on 03/27/24
  • Latest Earnings Date 05/08/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.03
  • Growth Rate Est. (year over year) +3,330,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1892 +1.48%
on 04/17/24
0.4300 -55.35%
on 03/22/24
-0.1080 (-36.00%)
since 03/15/24
3-Month
0.1805 +6.37%
on 01/25/24
0.4300 -55.35%
on 03/22/24
-0.0180 (-8.57%)
since 01/17/24
52-Week
0.1103 +74.07%
on 08/10/23
0.8900 -78.43%
on 10/11/23
-0.2525 (-56.81%)
since 04/17/23

Most Recent Stories

More News
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 265.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the...

MTNB : 0.1920 (-3.95%)
NOTV : 5.42 (-3.56%)
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 0.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

MTNB : 0.1920 (-3.95%)
CNCE : 8.37 (+0.12%)
Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022 FDA Provides Flexibility...

MTNB : 0.1920 (-3.95%)
Matinas BioPharma to Participate in the BTIG Biotechnology Conference

BEDMINSTER, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 0.1920 (-3.95%)
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022

BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical...

MTNB : 0.1920 (-3.95%)
Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis

BEDMINSTER, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 0.1920 (-3.95%)
BTIG Remains a Buy on Matinas BioPharma (MTNB)

BTIG analyst Robert Hazlett reiterated a Buy rating on Matinas BioPharma (MTNB – Research Report) on July 12 and set a price target of $3.00. The company's shares closed last Wednesday at $0.82. According...

MTNB : 0.1920 (-3.95%)
Matinas BioPharma to Present at the LD Micro Invitational XII Conference

BEDMINSTER, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 0.1920 (-3.95%)
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

MTNB : 0.1920 (-3.95%)
PRPH : 6.27 (-14.69%)
Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights

– Announced an exclusive research collaboration with BioNTech focused on the combination of mRNA and Matinas’ proprietary LNC platform technology – ...

MTNB : 0.1920 (-3.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines,...

See More

Key Turning Points

3rd Resistance Point 0.2207
2nd Resistance Point 0.2139
1st Resistance Point 0.2029
Last Price 0.1920
1st Support Level 0.1851
2nd Support Level 0.1783
3rd Support Level 0.1673

See More

52-Week High 0.8900
Fibonacci 61.8% 0.5922
Fibonacci 50% 0.5001
Fibonacci 38.2% 0.4081
Last Price 0.1920
52-Week Low 0.1103

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar